Clinical Asset ConcernsThere is a lack of confidence that the shortcomings of the company's prior programs will be adequately addressed with different targets and indications.
Revenue And LossesFor 1Q25, the company reported no revenue and a net loss of $0.13 per share.
Strategic UncertaintiesUncertainties are generated regarding the company’s only clinical asset, LAVA-1266 for hematological malignancies, as it depends on the outcome of the strategic review.